12:00 AM
May 12, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nexavar sorafenib regulatory update

EMA's CHMP issued a positive opinion recommending expanding the label for Nexavar sorafenib to include treatment of progressive, locally advanced or metastatic, differentiated thyroid cancer in patients who no longer respond to treatment with radioactive iodine. Bayer...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >